XML 30 R20.htm IDEA: XBRL DOCUMENT v3.26.1
SEGMENT REPORTING
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
SEGMENT REPORTING

10. SEGMENT REPORTING

 

The Company manages its operations as a single operating segment, which includes all activities related to the development and potential commercialization of novel therapies for the treatment of cancer, for the purposes of assessing performance and making operating decisions. The determination of a single business segment is consistent with the consolidated financial information regularly provided to the Company’s chief operating decision maker (“CODM”). The Company’s CODM is its President and Chief Executive Officer, who reviews and evaluates consolidated net income (loss) for purposes of assessing performance, making operating decisions, allocating resources, and planning and forecasting for future periods.

 

In addition to the significant expense categories included within consolidated net income (loss) presented on the Company’s unaudited condensed consolidated statements of operations, see below for disaggregated amounts that comprise research and development expenses for the three months ended March 31, 2026 and 2025:

              
   Three Months Ended March 31, 
   2026   2025 
Personnel and consulting expenses  $1,209,211   $856,693 
External clinical study expenses   581,189    1,834,371 
Nonclinical and biomarker studies   538,077    92,401 
Chemistry Manufacturing & Control (“CMC”) related costs   236,767    436,854 
Total research and development expenses  $2,565,244   $3,220,319 

 

In addition, the Company has a wholly-owned subsidiary, Actuate Therapeutics Limited, which is a dormant entity with no assets, liabilities or operations in any foreign countries.